In this podcast, Chuck Vega, MD speaks about the financial implications of various treatments for patients with community-acquired bacterial pneumonia (CABP) and for the care system. He also speaks about...
In this podcast, Daniel M. Musher, MD, answers our questions on his systematic review of the etiology of community-acquired pneumonia and briefly discusses his extensive research on community-acquired...
In this podcast, Chuck Vega, MD, speaks about how clinicians determine site and duration of treatment for community-acquired bacterial pneumonia (CABP) based on patients' factors and prior treatment,...
Forest Arnold, MD, and Michael Egger, MD, speak about their study that aimed to evaluate the cost-effectiveness of adhering to treatment guidelines for community-acquired bacterial pneumonia in elderly...
